drugset
drugset / Trial / NCT01904318

A Phase I Study of IDP-73152 Mesylate in Health Male Volunteer

NCT01904318 ↗

Phase 1 Completed 56 enrolled IlDong Pharmaceutical Co Ltd
RandomizedParallel-groupDouble-blindTreatment

Summary

A dose block-randomized, double-blinded, placebo-controlled, single dose, dose-escalation clinical phase I study to evaluate the safety, pharmacokinetics and food effect of IDP-73152 mesylate after oral administration in healthy male volunteer

Timeline

Start
2013-07
Primary completion
2013-12
Completion
2014-01

Drugs

EvaluationDrugModalityDoseRoute
Subject IDP-73152 Unknown 40 mg Oral
Subject IDP-73152 Unknown 80 mg Oral
Subject IDP-73152 Unknown 160 mg Oral
Subject IDP-73152 Unknown 320 mg Oral
Subject IDP-73152 Unknown 640 mg Oral
Subject IDP-73152 Unknown 1280 mg Oral

Indications

No indication recorded.